10 results about "Drug additive" patented technology

Disclosed herein are high throughput, efficient, and simplified unloading and packaging systems and methods for large-scale production of pharmaceutical units using additive manufacturing. The disclosed systems and methods may unload, inspect, package, and trace pharmaceutical units, produced by an additive manufacturing system, that are not damaged or deformed. The unloading and packaging system can include one or more unloading and packaging devices. The unloading and packaging device can include a modular configuration having modules. Individual modules to be arranged in any relative order, at any location, and with any number in the unloading and packaging device. The flexibility of the modular configuration allows one or more modules to be removed or added at any given time due to, e.g., expansion, downsizing, module repair, module upgrades, etc. High throughput can be achieved by operating unloading and packaging devices independently and in parallel.

In certain aspects, the present disclosure provides a lyophilized pharmaceutical formulation comprising a recombinant fusion protein and one or more pharmaceutical additives and / or excipients, the recombinant fusion protein comprises an extracellular domain (ECD) of a human activin receptor type IIA (ActRIIa) protein or a derivative thereof linked to a constant domain of an immunoglobulin, such as a human IgG1 Fc domain.

In certain aspects, the present disclosure provides a lyophilized pharmaceutical formulation comprising a recombinant fusion protein comprising the extracellular domain (ECD) of human activin receptor type IIA (ActRIIa) protein or a derivative thereof linked to a constant domain of an immunoglobulin, such as a human IgG1 Fc domain, and one or more pharmaceutical additives and / or excipients.

The application discloses a preparation method and application of canthaxanthin, and comprises the following steps: in the presence of beta-carotene, a catalyst, an additive and a solvent, the canthaxanthin is prepared by reaction at a temperature of-20 DEG C to 20 DEG C for 5-24 hours; the catalyst comprises a mixture of chlorate, metal iodide and inorganic acid; the additive comprises a mixture of raw materials represented by formula I, formula II and formula III, wherein the mass ratio of the raw materials represented by formula I, formula II and formula III is 1:(1.0-5.0):(1.0-5.0); and the total additive amount of the additive is 0.01-1 times the mass of the beta-carotene. The preparation method of the canthaxanthin has the characteristics of fast reaction speed, high product yield, less generation of three wastes, strong coloring capacity of the product and excellent thermal stability, and has great competitive advantage in the field of food and drug additives.

In certain aspects, the present disclosure provides lyophilized pharmaceutical formulations comprising a recombinant fusion protein comprising an extracellular domain (ECD) of human activin receptor type-IIA (ActRIIa) proteins or derivatives thereof linked to a constant domain of an immunoglobulin, such as human IgG1 Fc domain and one or more pharmaceutical additives and / or excipients.

The invention discloses an intake water quality purification treatment ship pump station system, and relates to the technical field of water quality purification, the intake water quality purification treatment ship pump station system comprises a mounting rack, a water pump device is fixedly mounted in the mounting rack, two sets of intake water purification components are further arranged in the mounting rack, a water inlet pipe is externally connected to a water inlet of the water pump device, and a three-way valve pipe is communicated to a water outlet of the water pump device; the water source purification capacity of the water sampling ship pump is improved, meanwhile, the water taking and producing process can be continuously carried out, water pump equipment does not need to be shut down, the real turbidity of taken water is corrected according to the data condition, the real turbidity of the taken water is corrected, and the accuracy of the water sampling ship pump is improved. The condition that data collected by the turbidity sensor is deviated due to multiple interference factors is eliminated, the dosage is regulated and controlled according to a correction result, so that the matching performance of the medicine additive dosage and the actual situation of pumped water is higher, and the adverse conditions that the produced water is turbid due to insufficient addition or the produced water is too much added and more residues exist are not prone to occurring.

In certain aspects, the present disclosure provides a stable liquid pharmaceutical formulation comprising a recombinant fusion protein comprising the extracellular domain (ECD) of human activin receptor type IIA (ActRIIA) protein or a variant thereof linked to a constant domain of an immunoglobulin, such as a human IgG1 Fc domain, and one or more pharmaceutical additives and / or excipients.

The invention relates to the technical field of animal feed, in particular to a cattle and sheep weaning concentrate formula, which consists of the following components in percentage by weight: 50 to 85 percent of energy-protein base material, 10 to 40 percent of plant function formula, 2 to 8 percent of mineral supplement, 0.5 to 3 percent of microbial regulator and 0 to 0.5 percent of optional drug additive, the plant functional formula is prepared by compounding Chinese herbal medicines with the functions of tonifying spleen and promoting appetite, clearing away heat and toxic materials and tonifying according to the weight ratio of (3-5): (1-3): (2-4), and preferably, the ratio of red date powder to dandelion powder to astragalus membranaceus powder to liquorice powder to elm leaf powder is 2: 1.5: 2: 1: 1.5; traditional breeding experience and modern nutrition technology are integrated, the problems of reduced feed intake, dyspepsia, low immunity, growth retardation and the like of cattle and sheep in the weaning period are solved in a targeted manner through a multi-component synergistic effect, and the feed does not need to depend on antibiotics, is high in safety and low in cost and can be prepared into dry powder or granular feed for use.

This invention relates to the field of organoid bioprinting technology, and discloses a method for preparing articular cartilage organoids, a bio-ink for encapsulating articular cartilage organoids, the preparation method thereon, and their applications. The preparation method includes: pretreating the raw material to be cultured in a basal culture medium containing a nanomedicine additive, wherein the nanomedicine additive chemically comprises mesoporous silica nanoparticles loaded with docetaxel and polyethyleneimine modified on the mesoporous silica nanoparticles; culturing the pretreated raw material in a cartilage organoid induction culture medium containing docetaxel; wherein the raw material to be cultured contains bone marrow mesenchymal stem cells. The articular cartilage organoids prepared by this method have a distinct cartilage-bone bio-interface, and the pretreatment process can help maintain the long-term phenotype of the cartilage organoids by inhibiting endochondral ossification during their development.

In certain aspects, the present disclosure provides stable, liquid pharmaceutical formulations comprising a recombinant fusion protein comprising an extracellular domain (ECD) of human activin receptor type-IIA (ActRIIA) protein or variant thereof linked to a constant domain of an immunoglobulin, such as human IgG1 Fc domain and one or more pharmaceutical additives and / or excipients.